Modulatory Impact of Subsp. BL21 on the Gut-brain-ovary Axis in Polycystic Ovary Syndrome: Insights into Metabolic Regulation, Inflammation Mitigation, and Neuroprotection

Overview

Journal mSphere

Publisher American Society for Microbiology

Date 2025 Feb 3

PMID 39898662

Authors

Yao Dong

Shengnan Yang

Shu Zhang

Yuan Zhao

Xinlan Li

Mei Han

Zhonghui Gai

Kang Zou

Affiliations

Soon will be listed here.

Abstract

This study evaluates the efficacy of subsp. BL21 in mitigating symptoms of polycystic ovarian syndrome (PCOS) in DHT-induced PCOS model mice. It focuses on BL21's role in modulating metabolic dysregulation, inflammation, and neuroprotection via the gut-brain-ovary axis. Employing an 8-week treatment regimen, this research assessed the effects of BL21 on prenatal androgen-induced PCOS in ICR mice. Evaluations included body weight, glucose tolerance tests, serum analyses of BDNF, inflammatory markers, sex hormone levels, and 16S rRNA gene sequencing for gut microbiota diversity and composition. Twenty-four ICR mice with induced PCOS served as subjects to examine the probiotic's impact. Mice were administered a daily oral dose of 1 × 10 CFU of BL21 continuously for a total of 8 weeks. BL21 significantly enhanced sex hormone levels ( < 0.05), particularly those of follicle-stimulating hormone (FSH) and estradiol (E2), indicating improved ovarian function and offering a novel PCOS treatment approach. The intervention notably curbed weight gain and improved glucose tolerance in PCOS mice ( < 0.05). BL21 reduced inflammatory markers such as interleukin-6 (IL-6), tumor necrosis factor-alpha (TNF-α), and lipopolysaccharides (LPS), while increasing IL-10, BDNF, FSH, and E2 levels ( < 0.05 for all). It also enriched gut microbiota diversity, enhancing populations of and . Correlation analyses underscored the positive shifts in microbiota linked to beneficial hormonal and inflammatory profiles. BL21 shows promise in alleviating PCOS symptoms through metabolic regulation, inflammation reduction, and neuroprotection, validating its potential in integrated therapeutic strategies.IMPORTANCEPolycystic ovarian syndrome (PCOS) is a prevalent endocrine disorder affecting women of reproductive age, characterized by metabolic irregularities, hormonal imbalances, and chronic inflammation. Existing treatments are often inadequate, addressing symptoms without targeting the underlying etiological factors. The investigation of subsp. BL21 as a probiotic intervention offers a novel approach by potentially regulating the gut-brain-ovary axis. This could lead to innovative therapeutic strategies that not only manage but also potentially reverse the multifaceted symptoms of PCOS, enhancing quality of life and reproductive health.

References

. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil Steril. 2004; 81(1):19-25. DOI: 10.1016/j.fertnstert.2003.10.004. View

Xia Q, Zhang D, Wang J, Zhang X, Song W, Chen R . Androgen Indirectly Regulates Gap Junction Component Connexin 43 Through Wilms Tumor-1 in Sertoli Cells. Stem Cells Dev. 2019; 29(3):169-176. DOI: 10.1089/scd.2019.0166. View

Zhang Y, Chen D, Wang D, Wang L, Weng Y, Wang H . Moderate Aerobic Exercise Regulates Follicular Dysfunction by Initiating Brain-Derived Neurotrophic Factor (BDNF)-Mediated Anti-Apoptotic Signaling Pathways in Polycystic Ovary Syndrome. J Clin Med. 2022; 11(19). PMC: 9571561. DOI: 10.3390/jcm11195584. View

Sirmans S, Pate K . Epidemiology, diagnosis, and management of polycystic ovary syndrome. Clin Epidemiol. 2014; 6:1-13. PMC: 3872139. DOI: 10.2147/CLEP.S37559. View

Moore A, Prescott M, Campbell R . Estradiol negative and positive feedback in a prenatal androgen-induced mouse model of polycystic ovarian syndrome. Endocrinology. 2012; 154(2):796-806. DOI: 10.1210/en.2012-1954. View

Langille M, Zaneveld J, Caporaso J, McDonald D, Knights D, Reyes J . Predictive functional profiling of microbial communities using 16S rRNA marker gene sequences. Nat Biotechnol. 2013; 31(9):814-21. PMC: 3819121. DOI: 10.1038/nbt.2676. View

Zhang X, Yang Y, Xia Q, Song H, Wei R, Wang J . Cadherin 22 participates in the self-renewal of mouse female germ line stem cells via interaction with JAK2 and β-catenin. Cell Mol Life Sci. 2017; 75(7):1241-1253. PMC: 11105442. DOI: 10.1007/s00018-017-2689-4. View

Hao J, Zhang Y, Wu T, Liu R, Sui W, Zhu J . The antidiabetic effects of BL21 through regulating gut microbiota structure in type 2 diabetic mice. Food Funct. 2022; 13(19):9947-9958. DOI: 10.1039/d2fo01109c. View

Hashimoto Y, Tachibana K, Krug S, Kunisawa J, Fromm M, Kondoh M . Potential for Tight Junction Protein-Directed Drug Development Using Claudin Binders and Angubindin-1. Int J Mol Sci. 2019; 20(16). PMC: 6719960. DOI: 10.3390/ijms20164016. View

10.

Alizadeh A, Akbari P, Garssen J, Fink-Gremmels J, Braber S . Epithelial integrity, junctional complexes, and biomarkers associated with intestinal functions. Tissue Barriers. 2021; 10(3):1996830. PMC: 9359365. DOI: 10.1080/21688370.2021.1996830. View

11.

Streiter S, Fisch B, Sabbah B, Ao A, Abir R . The importance of neuronal growth factors in the ovary. Mol Hum Reprod. 2015; 22(1):3-17. DOI: 10.1093/molehr/gav057. View

12.

Dumesic D, Oberfield S, Stener-Victorin E, Marshall J, Laven J, Legro R . Scientific Statement on the Diagnostic Criteria, Epidemiology, Pathophysiology, and Molecular Genetics of Polycystic Ovary Syndrome. Endocr Rev. 2015; 36(5):487-525. PMC: 4591526. DOI: 10.1210/er.2015-1018. View

13.

Escobar-Morreale H . Polycystic ovary syndrome: definition, aetiology, diagnosis and treatment. Nat Rev Endocrinol. 2018; 14(5):270-284. DOI: 10.1038/nrendo.2018.24. View

14.

Chen K, Geng H, Liu J, Ye C . Alteration in gut mycobiota of patients with polycystic ovary syndrome. Microbiol Spectr. 2023; :e0236023. PMC: 10580825. DOI: 10.1128/spectrum.02360-23. View

15.

Rudnicka E, Suchta K, Grymowicz M, Calik-Ksepka A, Smolarczyk K, Duszewska A . Chronic Low Grade Inflammation in Pathogenesis of PCOS. Int J Mol Sci. 2021; 22(7). PMC: 8038770. DOI: 10.3390/ijms22073789. View

16.

Borthakur A, Prabhu Y, Gopalakrishnan A . Role of IL-6 signalling in Polycystic Ovarian Syndrome associated inflammation. J Reprod Immunol. 2020; 141:103155. DOI: 10.1016/j.jri.2020.103155. View

17.

Pauline M, Fouhse J, Hinchliffe T, Wizzard P, Nation P, Huynh H . Probiotic treatment vs empiric oral antibiotics for managing dysbiosis in short bowel syndrome: Impact on the mucosal and stool microbiota, short-chain fatty acids, and adaptation. JPEN J Parenter Enteral Nutr. 2022; 46(8):1828-1838. DOI: 10.1002/jpen.2377. View

18.

Zhang Q, Wu Y, Fei X . Effect of probiotics on glucose metabolism in patients with type 2 diabetes mellitus: A meta-analysis of randomized controlled trials. Medicina (Kaunas). 2016; 52(1):28-34. DOI: 10.1016/j.medici.2015.11.008. View

19.

Yin W, Huang C, Chen Y, Yu D, Jin M, Feng C . The effect of medication on serum anti-müllerian hormone (AMH) levels in women of reproductive age: a meta-analysis. BMC Endocr Disord. 2022; 22(1):158. PMC: 9195431. DOI: 10.1186/s12902-022-01065-9. View

20.

Bathina S, Das U . Brain-derived neurotrophic factor and its clinical implications. Arch Med Sci. 2016; 11(6):1164-78. PMC: 4697050. DOI: 10.5114/aoms.2015.56342. View